Collegium Pharmaceutical, Inc. Other Comprehensive Income (Loss), Net of Tax
Collegium Pharmaceutical, Inc. (COLL) reported Other Comprehensive Income (Loss), Net of Tax of $219.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was $219.00K, a 128.13% increase year-over-year.
- Collegium Pharmaceutical, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$538.00K, a 389.25% decline year-over-year.
- Collegium Pharmaceutical, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$45.00K, a 107.83% decline year-over-year.
- Collegium Pharmaceutical, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was $96.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month |
|---|---|---|---|
| 2026-06-30 | $219.00K 10-Q · filed 2026-08-06 | -$319.00K derived: sum of 2 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$538.00K 10-Q · filed 2026-08-06 | ||
| 2025-09-30 | -$45.00K 10-Q · filed 2025-11-06 | $51.00K derived: sum of 2 quarters · filed 2026-08-06 | $237.00K derived: sum of 3 quarters · filed 2026-08-06 |
| 2025-06-30 | $96.00K 10-Q · filed 2026-08-06 | $282.00K derived: sum of 2 quarters · filed 2026-08-06 | |
| 2025-03-31 | $186.00K 10-Q · filed 2026-08-06 | ||
| 2024-09-30 | $575.00K 10-Q · filed 2025-11-06 | $517.00K derived: sum of 2 quarters · filed 2025-11-06 | $379.00K derived: sum of 3 quarters · filed 2025-11-06 |
| 2024-06-30 | -$58.00K 10-Q · filed 2025-11-06 | -$196.00K derived: sum of 2 quarters · filed 2025-11-06 | |
| 2024-03-31 | -$138.00K 10-Q · filed 2025-11-06 | ||
| 2023-09-30 | -$14.00K 10-Q · filed 2024-11-07 | -$52.00K derived: sum of 2 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$38.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |